Insulin-degrading enzyme (IDE, also called insulysin or insulinase) is a zinc-dependent peptidase that hydrolyzes several bioactive peptides, notably insulin and the amyloid beta peptide. Because of these substrates, IDE has been proposed as a therapeutic target relevant to metabolic disease and Alzheimer’s disease. Despite extensive study, aspects of IDE’s physiological roles and cellular regulation remain unresolved.
The source study sought to further define IDE’s role in cells by identifying proteins that interact with IDE and determining whether such partners modulate its activity.
Using co-immunoprecipitation experiments, the investigators screened for proteins that associate with IDE. The enzyme pyrroline-5-carboxylate reductase 1 (PYCR1) was repeatedly identified as an IDE-associated protein across three distinct cell lines. The repeated detection in multiple cell types supports the reproducibility of the association under the experimental conditions described in the preprint.
Complementing the biochemical association data, the authors report that IDE and PYCR1 colocalize in HeLa cells. The colocalization finding supports the potential for a physiologically relevant interaction within cells, although the source does not provide additional details about subcellular localization patterns beyond colocalization in HeLa cells.
To assess functional consequences of the interaction, purified PYCR1 was tested for effects on IDE activity in vitro. The preprint reports that purified PYCR1 activates IDE toward small peptide substrates. This activation suggests a modulatory role for PYCR1 on IDE catalytic function and raises the possibility that PYCR1 could regulate IDE activity in vivo.
The authors used modeling to explore a possible structural basis for the observed activation. Modeling results indicate that the unstructured N‑terminal region of PYCR1 can insert into allosteric sites of IDE, which could account for the activation of peptide hydrolysis. The modeling provides a mechanistic hypothesis linking PYCR1’s structural features to modulation of IDE function.
To test the role of the N‑terminal sequence, the study examined the impact of deleting this region of PYCR1. Deletion altered the interaction between PYCR1 and IDE but did not eliminate it entirely. This outcome implies that while the N‑terminal region contributes to binding or modulation—consistent with the modeling—additional regions or mechanisms also support the interaction.
PYCR1 is a mitochondrial enzyme involved in proline biosynthesis. Given PYCR1’s mitochondrial localization, the authors propose that the IDE–PYCR1 interaction could regulate a previously described mitochondrial pool of IDE. They suggest this regulation might influence degradation of mitochondrial targeting sequences or of amyloid beta that localizes to mitochondria. The preprint frames these ideas as plausible functional consequences to be explored further rather than as established findings.
This report is a preprint posted July 19, 2026, and has not undergone peer review. The source presents co-immunoprecipitation, colocalization, in vitro activation assays with purified proteins, and structural modeling; however, detailed experimental parameters, quantitative data, and broader validation experiments are not included in the summary provided here. Any mechanistic and physiological interpretations are therefore provisional and derived from the experiments and modeling described in the preprint.
The preprint documents a reproducible association between IDE and PYCR1 across multiple cell lines and reports that purified PYCR1 can activate IDE toward small peptide substrates. Structural modeling implicates the unstructured N‑terminal region of PYCR1 in engaging allosteric sites on IDE, and deletion of that region modifies but does not abolish the interaction. Because PYCR1 is mitochondrial, the authors propose that this interaction may regulate a mitochondrial population of IDE, with potential implications for the degradation of mitochondrial targeting sequences or mitochondrial amyloid beta. Further peer-reviewed studies will be needed to validate these findings, quantify effects in physiological contexts, and determine the relevance for disease-related substrates such as insulin and amyloid beta.